University of Florida Veterinarians Seek Dogs for Stem Cell Studies to Treat Chronic Orthopedic Disease

A major gift to the University of Florida College of Veterinary Medicine will support two groundbreaking studies focusing on the use of stem cells as an alternative to surgery to treat a chronic degenerative joint disease in dogs.

“Stem cells collected from healthy donor dogs may offer a nonsurgical option for dogs with pain and stiffness from osteoarthritis of the knee and elbow,” said Antonio Pozzi, D.V.M., an associate professor of small animal surgery at UF.

Made possible through a $330,000 gift from Robert and Janet Sabes and the Sabes Foundation, the studies will track the effectiveness of stem cells injected into the knee joints of dogs with osteoarthritis due to a ruptured cranial cruciate ligament — known in humans as the anterior cruciate ligament, or ACL. Another study will focus on the treatment of elbow osteoarthritis secondary to elbow dysplasia, a common disease in large breed dogs.

UF veterinarians are currently seeking up to 60 dogs to participate in the study. Eligible dogs should be showing signs of lameness or limping for at least six months but are still weight-bearing, Pozzi said. Eligible dogs are also on anti-inflammatory medication and are 2 to 10 years old.

The treatment is free for study participants, but the dog’s owner must cover the cost of the initial evaluation.

“The long-term goal is to try to effectively treat dogs with chronic cranial cruciate ligament rupture and osteoarthritis without surgery,” Pozzi said. “The other key goal is to improve quality of life for the dog, decrease pain and improve limb function and mobility.”

Pozzi said most dogs that have shown signs of lameness for less than six months would probably benefit most from surgery, whereas older dogs, or dogs with ongoing osteoarthritis, may be better candidates for this stem cell treatment.

These specific studies have never previously been performed in dogs and could yield valuable data about how effective this treatment can be, Pozzi said.

“We are going to be approaching this in the most scientific way we can to really test the validity and effectiveness of stem cell treatment in dogs,” Pozzi said.

UF veterinarians will assess orthopedic function, as well as activity and quality of life of the dogs to see if their conditions improve. After initial treatment, the dogs will be evaluated after one, three and six months to determine levels of inflammation.

Pozzi said it is common for dogs with cruciate ligament injury in one leg to soon see the same problem in the opposite leg. In the future, UF veterinarians also hope to explore whether stem cell injections in the opposite leg might be able to delay or prevent cruciate ligament injury.

“Stem cell research is the future for the advancement of longevity in both humans and animals, as well as the future of disease prevention and cure,” said Robert Sabes. “The Sabes Foundation has donated to many medical research programs in the hope of further advancement of stem cell technology.”

He added that he and his wife, Janet, as board trustees of the foundation, feel that there is no more important area worthy of support in today’s world.

“This area of research is something that affects us all, as well as our closest friends and companions — our dogs,” he said.

Anyone seeking more information about the UF stem cell studies in dogs should contact Dr. Scott Christopher at 352-294-4479, sachristopher@ufl.edu or Christina Bonner at 858-678-8843, Christina@actcells.com.

Animal Cell Therapies, Inc. and University of Florida Receive $330k Grant from The Sabes Foundation for Stem Cell Study

This commitment demonstrates that we are dedicated to propelling innovation and providing solutions for veterinarians, pets and pet owners.

San Diego, CA (PRWEB) February 20, 2013 — Animal Cell Therapies, Inc. of San Diego and the University of Florida has received a $330k grant from The Sabes Foundation to fund a study about orthopedic conditions in dogs.

Animal Cell Therapies Inc. is an early stage Veterinary stem cell therapy company whose mission is to deliver a new frontier of stem cell therapies for the treatment of canine orthopedic conditions.

The Sabes Foundation grant will be used to study the potential of mesenchymal stem cells to treat orthopedic conditions in dogs. This research may also be translational across human medicine. The main investigator leading this study will be Dr. Antonio Pozzi, DVM at the University of Florida.

“This grant is fundamental to providing answers about the mechanism of stem cell activity in orthopedic conditions in dogs,” said Dr. Kathryn Petrucci, founder of Animal Cell Therapies, Inc.

“The Sabes Foundation has a special interest and focus in the funding of cutting edge medical research and treatment of animals and humans particularly involving the use of stem cells,” said Robert Sabes of The Sabes Foundation.

The Sabes Foundation was founded by Moe and Esther Sabes in order to enrich the lives of the members of the community through contributions to organizations and people that support that mission. The Foundation’s tradition of giving has continued through the stewardship of Robert and Janet Sabes. The Foundation hascontinued to support the development of the humanities through a wide variety of gifts and grants to both Jewish and secular causes.

The Sabes Family Foundation looks to enrich communities through supporting a variety of gifts and grants –ranging from the Sabes Jewish Community Center, to the Howard Pulley youth basketball tournament. Through the leadership of Robert Sabes, the Foundation has developed strong financial commitments with unique community assets that serve to culturally enrich our lives. To learn more, go to: sabesfoundation.org.

About Animal Cell Therapies

Founded in January 2008 in San Diego, California, Animal Cell Therapies Inc. is the manifestation of veterinarian Dr. Kathryn Petrucci, whose vision is to improve the lives of animals through thoughtful research and development, innovation and strategic partnerships. At the company’s California-based stem cell research and development facility, the team is focused on developing and delivering revolutionary cellular treatment and services to their customers. For more information, visit: www.actcells.com

 

Animal Cell Therapies, Inc. is pleased to announce the appointment of Robert Sabes as chairman of its Business Advisory board.

San Diego – February 12, 2012 – Animal Cell Therapies (ACT), a company specializing in scientific based veterinary stem cell treatments and products, announced today the appointment of Robert Sabes as chairman of its Business Advisory Board.

Possessing decades of investment and management experience in a wide variety of industries, Robert Sabes currently presides as the Chairman and Chief Executive Officer of RW Sabes Enterprises.

“Animal Cell Therapies welcomes the wealth of business expertise that Mr. Sabes provides as chairman of our business advisory board,” said Dr. Kathryn Petrucci, founder of Animal Cell Therapies, Inc.”

About Animal Cell Therapies

Founded in January 2008 in San Diego, California, Animal Cell Therapies (ACT) is the manifestation of veterinarian Dr. Kathryn Petrucci, whose vision is to improve the lives of animals through thoughtful research and development, innovation and strategic partnerships.  At the company’s California-based stem cell research and development facility, the ACT team is focused on developing and delivering revolutionary cellular treatment and services to their customers.  For more information, visit www.actcells.com.

Dr. Leo Furcht Appointed to Board of Directors

SAN DIEGO – June 12, 2012 – Animal Cell Therapies, Inc. a veterinarian regenerative medicine company is pleased to announce the appointment of Leo T. Furcht, M.D. to its Board of Directors.

Dr. Furcht, Department Chair of the Laboratory Medicine and Pathology at the University of Minnesota, brings a wealth of scientific and commercial experience from the field of regenerative medicine.  His work includes co-author of the book The Stem Cell Dilemma and holding several key patents in the adult stem cell field.   “The addition of Dr. Furcht to our Board of Directors brings tremendous value,” said Adam Irving, chief executive officer of Animal Cell Therapies.  “He has published over 175 scientific papers, developed 30 plus patents and founded a number of companies. Dr. Furcht is an excellent complement to our plan.”

“Dr. Furcht’s combination of scientific and business experience along with stem cell expertise will be invaluable to the future of Animal Cell Therapies,” said Kathy Petrucci, founder and chief medical offer of Animal Cell Therapies.

Dr. Furcht has successfully founded and developed numerous businesses including MCL, a stem cell research company that utilized adult stem cells as an effective replacement for embryonic stem cells.  He was the co-founder of South Bay Medical, a medical device company that was acquired by Mentor Corporation in 2001.

Dr. Furcht also serves as Chairman of the Board of Directors for University of Minnesota Physicians and is also the founding director of the Biomedical Engineering Center of the University of Minnesota.  Dr. Furcht is originally from New York where he did his undergraduate and pre-med work at Columbia University.  He received his MD at SUNY Upstate and his residency training at the University of Minnesota where he has been on the faculty since.

About Animal Cell Therapies

Founded in January 2008 in San Diego, California, Animal Cell Therapies (ACT) is the manifestation of veterinarian, Dr. Kathryn Petrucci, whose vision is to improve the lives of animals through thoughtful research and development, innovation and strategic partnerships. At the Company’s California-based stem cell research and development facility, the ACT team is focused on developing and delivering revolutionary cellular treatment and services to their customers. For more information, visit www.actcells.com.